title: [Antihypertensive therapy and dynamics of vascular wall rigidity in elderly patients with non-valvular atrial fibrillation].
abstract: This comparative ultrasound study included 210 patients aged 65-80 years with non-valvular atrial fibrillation treated with the use of 4 different therapeutic modalities. Intake of perindopril, valsartan, valsartan + rozuvastatin, and lercanidipine resulted in a rise in distension index of common carotid artery, decrease of rigidity coefficient of the aortic wall and increase of the pulsed wave propagation speed. Combination of valsartan (80-160 mg/d) and rozuvastatin (10 mg/d) had the most pronounced effect on the vascular wall compliance compared with other modalities and reduced the frequency of ischemic stroke, myocardial infarction, and mortality. It is concluded that therapy of non-valvular atrial fibrillation in elderly patients with valsartan + rozuvaststin is the optimal strategy for the improvement of elastic properties of the vascular wall and reduction of the frequency of cardiovascular complications.
authors.forename: V I
authors.initials: VI
authors.lastname: Shevelev
authors.forename: S G
authors.initials: SG
authors.lastname: Kanorskiĭ
mesh_terms: D000368:Aged; D055109:Ankle Brachial Index / Q000379:methods; D000924:Anticholesteremic Agents / Q000008:administration & dosage; D000959:Antihypertensive Agents / Q000008:administration & dosage; D062186:Arterial Pressure / Q000187:drug effects; D001158:Arteries / Q000000981:diagnostic imaging / Q000187:drug effects / Q000503:physiopathology; D001281:Atrial Fibrillation / Q000150:complications* / Q000503:physiopathology; D003131:Combined Modality Therapy / Q000379:methods / Q000592:standards; D016903:Drug Monitoring; D005260:Female; D005464:Fluorobenzenes / Q000008:administration & dosage*; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D009203:Myocardial Infarction / Q000209:etiology / Q000517:prevention & control; D020913:Perindopril / Q000008:administration & dosage*; D063177:Pulse Wave Analysis / Q000295:instrumentation / Q000379:methods; D011743:Pyrimidines / Q000008:administration & dosage*; D000068718:Rosuvastatin Calcium; D020521:Stroke / Q000209:etiology / Q000517:prevention & control; D013449:Sulfonamides / Q000008:administration & dosage*; D013777:Tetrazoles / Q000008:administration & dosage*; D016896:Treatment Outcome; D018616:Ultrasonography, Doppler, Duplex / Q000379:methods; D014633:Valine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000068756:Valsartan; D014655:Vascular Resistance / Q000187:drug effects
chemical_list: D000924:Anticholesteremic Agents; D000959:Antihypertensive Agents; D005464:Fluorobenzenes; D011743:Pyrimidines; D013449:Sulfonamides; D013777:Tetrazoles; D000068756:Valsartan; D000068718:Rosuvastatin Calcium; D014633:Valine; D020913:Perindopril